IDEXX Laboratories, Inc. (IDXX) Director Sells $1,234,117.76 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Director M Anne Szostak sold 5,906 shares of the firm’s stock in a transaction dated Thursday, February 14th. The stock was sold at an average price of $208.96, for a total transaction of $1,234,117.76. Following the completion of the transaction, the director now owns 6,490 shares of the company’s stock, valued at $1,356,150.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of NASDAQ IDXX traded up $1.06 during mid-day trading on Tuesday, reaching $211.32. The company had a trading volume of 484,100 shares, compared to its average volume of 552,948. The firm has a market capitalization of $18.13 billion, a price-to-earnings ratio of 49.61 and a beta of 1.02. IDEXX Laboratories, Inc. has a 12-month low of $176.11 and a 12-month high of $256.22.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Friday, February 1st. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.08. The business had revenue of $549.39 million during the quarter, compared to analyst estimates of $546.04 million. IDEXX Laboratories had a net margin of 17.03% and a negative return on equity of 1,501.97%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.43 earnings per share. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 4.69 EPS for the current fiscal year.



Several brokerages have commented on IDXX. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $236.00 target price for the company in a report on Monday, February 4th. Bank of America reduced their price target on shares of IDEXX Laboratories from $275.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, November 2nd. BidaskClub raised shares of IDEXX Laboratories from a “sell” rating to a “hold” rating in a research report on Thursday, January 24th. Finally, Canaccord Genuity reduced their price target on shares of IDEXX Laboratories from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Monday, November 5th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. IDEXX Laboratories currently has a consensus rating of “Buy” and an average target price of $246.00.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Pearl River Capital LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at approximately $28,000. Sontag Advisory LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at approximately $79,000. Quantamental Technologies LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at approximately $92,000. Migdal Insurance & Financial Holdings Ltd. raised its position in IDEXX Laboratories by 144.3% during the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 618 shares of the company’s stock valued at $154,000 after acquiring an additional 365 shares in the last quarter. Finally, Ipswich Investment Management Co. Inc. bought a new position in IDEXX Laboratories during the fourth quarter valued at approximately $124,000. 87.41% of the stock is owned by institutional investors and hedge funds.

WARNING: “IDEXX Laboratories, Inc. (IDXX) Director Sells $1,234,117.76 in Stock” was first reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this article on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this article can be viewed at https://dakotafinancialnews.com/2019/02/20/idexx-laboratories-inc-idxx-director-sells-1234117-76-in-stock.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Recommended Story: How analysts view the yield curve

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.